Related Experiment Video
Updated: Nov 15, 2025
08:16
Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
9.0K
KRAS mutation in pancreatic cancer
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Seminars in Oncology
|March 7, 2021
Summary
Pancreatic cancer has low survival rates, but new KRAS inhibitors show promise. Targeting the KRAS oncogene offers a potential therapeutic strategy for this challenging disease.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic cancer is a deadly disease with poor prognosis.
- The KRAS oncogene is frequently mutated and drives tumor growth.
- Current therapies targeting KRAS pathways have limited efficacy.
Purpose of the Study:
- To review the role of mutant KRAS in pancreatic cancer.
- To discuss emerging therapeutic strategies targeting KRAS signaling.
- To summarize recent advancements in KRAS-targeted therapies.
Main Methods:
- Literature review of studies on KRAS mutations in pancreatic cancer.
- Analysis of preclinical and clinical data for KRAS-targeted inhibitors.
- Synthesis of information on KRAS signaling pathways and therapeutic interventions.
Main Results:
- KRAS mutations are a key driver in pancreatic cancer.
- Covalent inhibitors targeting KRAS G12C demonstrate early clinical promise.
- Targeting KRAS signaling remains a critical therapeutic avenue.
Conclusions:
- Despite challenges, targeting KRAS offers a viable strategy for pancreatic cancer treatment.
- Novel KRAS inhibitors, particularly for KRAS G12C mutations, represent a significant advancement.
- Further research and clinical trials are essential to optimize KRAS-targeted therapies.
Related Concept Videos
02:38The Ras Gene
6.7K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.7K
02:23Abnormal Proliferation
4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
03:03mTOR Signaling and Cancer Progression
4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.0K
01:33Cancer-Critical Genes I: Proto-oncogenes
9.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.7K
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.5K
02:07Tumor Progression
6.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K